BR112022009942A2 - Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado - Google Patents

Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado

Info

Publication number
BR112022009942A2
BR112022009942A2 BR112022009942A BR112022009942A BR112022009942A2 BR 112022009942 A2 BR112022009942 A2 BR 112022009942A2 BR 112022009942 A BR112022009942 A BR 112022009942A BR 112022009942 A BR112022009942 A BR 112022009942A BR 112022009942 A2 BR112022009942 A2 BR 112022009942A2
Authority
BR
Brazil
Prior art keywords
liver
receptor agonists
oxadiazole derivatives
compound
formula
Prior art date
Application number
BR112022009942A
Other languages
English (en)
Inventor
D Boss Kelly
Fan Yi
Nathanson FLYER Alec
HARDY Declan
Huang Zhihong
Taylor LINKENS Kathryn
Christopher Loren Jon
Ma Fupeng
Molteni Valentina
Shaw Duncan
Smith Jeffrey
Fooks SOLOVAY Catherine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022009942A2 publication Critical patent/BR112022009942A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE 1,2,4-OXADIAZOL COMO AGONISTAS DO RECEPTOR X DO FÍGADO. A presente invenção refere-se a compostos e composições farmacêuticas úteis para tratar disfunção da glândula meibomiana (MGD) que compreendem administrar a um indivíduo que necessite do mesmo uma quantidade terapeuticamente eficaz de um composto da Fórmula (I) ou um composto da Fórmula (I'), ou composição farmacêutica descrita no presente documento.
BR112022009942A 2019-11-25 2020-11-23 Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado BR112022009942A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US202063106293P 2020-10-27 2020-10-27
PCT/IB2020/061053 WO2021105857A1 (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists

Publications (1)

Publication Number Publication Date
BR112022009942A2 true BR112022009942A2 (pt) 2022-08-09

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009942A BR112022009942A2 (pt) 2019-11-25 2020-11-23 Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado

Country Status (19)

Country Link
US (2) US11427586B2 (pt)
EP (1) EP4065228A1 (pt)
JP (1) JP2023503320A (pt)
KR (1) KR20220106778A (pt)
CN (1) CN114746149A (pt)
AU (1) AU2020394597B2 (pt)
BR (1) BR112022009942A2 (pt)
CA (1) CA3157657A1 (pt)
CL (1) CL2022001323A1 (pt)
CO (1) CO2022006645A2 (pt)
CR (1) CR20220227A (pt)
EC (1) ECSP22040362A (pt)
IL (1) IL291958A (pt)
JO (1) JOP20220124A1 (pt)
MX (1) MX2022006151A (pt)
PE (1) PE20221785A1 (pt)
TW (1) TW202132289A (pt)
UY (1) UY38964A (pt)
WO (1) WO2021105857A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4340808A1 (en) * 2021-05-20 2024-03-27 Novartis AG Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR20240059836A (ko) 2022-10-28 2024-05-08 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
US20200188297A1 (en) 2018-12-13 2020-06-18 eyeNOS, Inc. LXR Agonist in Topical Ophthalmic Formulation for Treatment of Dry-Eye Disorder

Also Published As

Publication number Publication date
ECSP22040362A (es) 2022-06-30
CA3157657A1 (en) 2021-06-03
AU2020394597A1 (en) 2022-06-02
CO2022006645A2 (es) 2022-05-31
EP4065228A1 (en) 2022-10-05
MX2022006151A (es) 2022-08-02
JP2023503320A (ja) 2023-01-27
UY38964A (es) 2021-06-30
US11427586B2 (en) 2022-08-30
AU2020394597B2 (en) 2024-03-14
KR20220106778A (ko) 2022-07-29
CR20220227A (es) 2022-06-15
US20220340573A1 (en) 2022-10-27
CL2022001323A1 (es) 2023-03-24
IL291958A (en) 2022-06-01
WO2021105857A1 (en) 2021-06-03
CN114746149A (zh) 2022-07-12
TW202132289A (zh) 2021-09-01
US20220064164A1 (en) 2022-03-03
JOP20220124A1 (ar) 2023-01-30
PE20221785A1 (es) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112022009942A2 (pt) Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
CR20230256A (es) Compuestos farmacéuticos
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112023019496A2 (pt) Derivados de ciclobutila 1,3-substituída e usos dos mesmos
BR112023000588A2 (pt) Derivados de piridazina como inibidores de alk5 e/ou alk4
BR112022001968A2 (pt) Formulações que incluem di-hidrohonokiol
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
BR112022018504A2 (pt) Usos de uma composição
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
BR112022017015A2 (pt) Ureia azalidas imunomoduladoras